Sharp Biomedical, a medical device company dedicated to accessible and manual procedures for outpatient pain clinics, announced on October 12, 2026, that it has closed its Pre-Seed funding round. The investment was led by gener8tor 1889, a North Dakota venture capital fund, with additional participation from multiple physician angel investors. The capital will fully fund the development and testing pathway needed to bring the company's first purpose-built toolset and implant system to market.
Funding Purpose and Strategic Focus
The new capital will support Sharp Biomedical's rigorous development program and testing protocols as the company advances toward regulatory milestones. The technology is designed specifically to fit within the workflow of outpatient pain clinics, offering a critical new option for patients with early-to-mid-stage chronic pain. Sharp Biomedical is pioneering a complementary path forward that relies on elegant, safe, and entirely manual procedures completed seamlessly within outpatient facilities.
Addressing an Unmet Need in Spine Care
Founder and CEO Dan Newman emphasized that while the industry is rightly focused on robotics and complex technologies for late-stage spinal care, a massive unmet need exists earlier in the care continuum. The company's approach broadens patient access by shifting effective interventions directly into local clinics without requiring intensive capital expenditures or major infrastructure overhauls. Newman said the Pre-Seed funding allows Sharp Biomedical to empower physicians with simple, safe, and reliable procedures.
Investor Confidence and Regional Impact
Ben Stanley, Principal of gener8tor 1889, described Dan Newman as an extremely impressive startup founder and said the firm has built significant conviction in him and the entire Sharp Biomedical team. Stanley noted that the company's mission to democratize access to spine care by empowering outpatient clinics with fast, safe, and reliable toolsets is refreshing in a highly complex industry. He also highlighted the team's continued commitment to growing the North Dakota biotech ecosystem.
Clinical Perspective from Physicians
Dr. Danny Neuman, Interventional Pain Specialist, Medical Staff President at Ascentist Healthcare, and advisor to Sharp Biomedical, said he is excited to partner with the company as it fills a vital gap in the market. He credited Sharp Biomedical's intelligent design process, which is rooted in collaborative input from physicians to directly address real clinical needs. According to Dr. Neuman, this partnership will allow earlier intervention in the care continuum and offer definitive relief right in the outpatient setting.
Path Toward Regulatory Milestones and Commercial Launch
With the Pre-Seed funding secured, Sharp Biomedical is moving forward with rigorous testing protocols and continued physician input. The company is positioning itself for its next regulatory milestones and the eventual commercial launch of its flagship device. Sharp Biomedical aims to reduce the industry's reliance on large hospital infrastructure, robotics, and prolonged operating times by designing manual procedures that require less operating time.
About Sharp Biomedical and Gener8tor
Sharp Biomedical is a medical device company focused on creating novel, streamlined toolsets and implants for spinal care. Gener8tor is a global venture firm and accelerator network that supports startups, founders, workers, employers, artists, and musicians across race, place, and gender. The firm partners with companies, governments, universities, and nonprofits to operate programs in more than 41 communities across 22 states and two countries.
Sharp Biomedical's successful Pre-Seed round marks an important step in expanding access to spine care for chronic pain patients. The support from gener8tor 1889 and physician angel investors validates the company's streamlined approach to outpatient treatment. As Sharp Biomedical advances toward regulatory clearance and commercial introduction, its focus on simple, safe, and manual procedures could offer a meaningful new option for clinics and patients alike.